References
Fukuoka M, Yano S, Giaccone G, et al. (2002) Final results from a phase II trial of ZD 1839 (‘Iressa’) for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21:298a [abstr 1188]
Haringhuizen A, van Tinteren H, Vaessen H H, Baas P, van Zandwijk N (2004) Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol 15:786–792
Inoune A, Saijo Y, Maemondo M, et al. (2003) Severe actue interstitial pneumonia and gefitinib. Lancet 361:137–139
Kris MG, Natale RB, Herbst R, et al. (2002) A phase II trial of ZD 1839 (‘Iressa’) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21: 292a [abstr 1166]
Kumasaka R, Nakamura N, Shirato K, et al. (2004) Side effects of the therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol 22:2504–2505
Rossi A, Maione P, Gaizo FD, et al. (2005) Safety profile of gefitinib in advanced non-small-cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 47:421–423
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wan, HL., Yao, NS. Acute Renal Failure Associated with Gefitinib Therapy. Lung 184, 249–250 (2006). https://doi.org/10.1007/s00408-005-2581-0
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00408-005-2581-0